Article ; Online: Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1.
2022 Volume 86, Issue Pt 2, Page(s) 126–135
Abstract: Considerable progress has been made in our understanding of the process of angiogenesis in the context of normal and tumor tissue over the last fifty years. Angiogenesis, like most physiological processes, is carefully controlled by dynamic and opposing ... ...
Abstract | Considerable progress has been made in our understanding of the process of angiogenesis in the context of normal and tumor tissue over the last fifty years. Angiogenesis, like most physiological processes, is carefully controlled by dynamic and opposing effects of positive factors, such as vascular endothelial growth factor (VEGF), and negative factors, such as thrombospondin-1. In most cases, the progression of a small mass of cancerous cells to a life-threatening tumor depends upon the initiation of angiogenesis and involves the dysregulation of the angiogenic balance. Whereas our newfound appreciation for the role of angiogenesis in cancer has opened up new avenues for treatment, the success of these treatments, which have focused almost exclusively on antagonizing the VEGF pathway, has been limited to date. It is anticipated that this situation will improve as more therapeutics that target other pathways are developed, more strategies for combination therapies are advanced, more detailed stratification of patient populations occurs, and a better understanding of resistance to anti-angiogenic therapy is gained. |
---|---|
MeSH term(s) | Humans ; Neoplasms/blood supply ; Neovascularization, Pathologic/genetics ; Neovascularization, Pathologic/metabolism ; Vascular Endothelial Growth Factor A/genetics ; Vascular Endothelial Growth Factor A/metabolism ; Thrombospondin 1/metabolism |
Chemical Substances | Vascular Endothelial Growth Factor A ; Thrombospondin 1 |
Language | English |
Publishing date | 2022-09-30 |
Publishing country | England |
Document type | Journal Article ; Research Support, Non-U.S. Gov't ; Review |
ZDB-ID | 1033980-2 |
ISSN | 1096-3650 ; 1044-579X |
ISSN (online) | 1096-3650 |
ISSN | 1044-579X |
DOI | 10.1016/j.semcancer.2022.09.006 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2922: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.